Technology News and Headlines

InflaRx Stanches Spending With 30% Staff Reduction, Priority Pivot

InflaRx announced a restructuring that will eliminate roughly 30% of its workforce and incur about $7 million in one‑time, largely non‑cash, costs. The company is pulling funding from its COVID‑19 antibody Gohibic and redirecting resources toward izicopan, an oral C5a‑receptor inhibitor in mid‑stage development for chronic spontaneous urticaria and hidradenitis suppurativa. Management expects the cost‑saving measures to extend its cash runway to mid‑2027 while it negotiates Phase IIb trial endpoints with the FDA. Data from Phase IIa studies are slated for presentation later this year.